RIPK1 and amyotrophic lateral sclerosis: Selective inhibitor of RIPK1 such as necrostain-1 has been applied in stroke (Zhang et al., 2016), traumatic spinal cord injury (Wang et al., 2014), and amyotrophic lateral sclerosis (Re et al., 2014; Ito et al., 2016) and reveals protection in CNS diseases (Degterev et al., 2019; Yuan et al., 2019).